MAZE · Maze Therapeutics Inc
United States · RS rating 79 · As of 2026-11-03
| Price | 32.25 USD |
|---|---|
| 1-day change | +6.2% |
| RS rating (overall / 1M / 3M / 12M) | 79 / 94 / 87 / 49 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 42 / 28 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +1.5% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +37.8% |
| Market cap (USD) | $1.4B |